Australian biotech market today 08.04.09

The pharma and biotech index is down one per cent at 3pm today, in line with the rest of the All Ordinaries.

The Big Three – Cochlear (ASX:COH), CSL (ASX:CSL) and ResMed (ASX:RMD) – have followed the rest of the index and are down on today’s trading.

Pharmaxis (ASX:PXS), which yesterday appointed US-based life science investment manager Richard van den Broek to its board, is up 8c to almost $2.

Novogen (ASX:NRT) is also up again today on very small volumes. The company today announced good results from a Phase II trial being carried out by one of its US subsidiaries, Glycotex, in wound healing. While this trial is in a cosmetic application, the company is also investigating its compound GLYC-101 in burns, surgical wounds and venous and diabetic ulcers.

Progen (ASX:PGL) is up again despite its recent dramas, settling at just over 90c today.

API manufacturer IDT Australia (ASX:IDT) is down 6c to $1.52, while Circadian (ASX:CIR) is up 3c and Clinuvel (ASX:CLV) is up 1c.